Akebia Therapeutics has been granted a patent for a method to treat anemia related to chronic kidney disease using a specific compound. The patent outlines specific doses and dosing regimens for treating anemia associated with various conditions like chemotherapy and AIDS. GlobalData’s report on Akebia Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Akebia Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Akebia Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Akebia Therapeutics's grant share as of January 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Treating anemia with specific doses of hif prolyl hydroxylase inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: Akebia Therapeutics Inc

A recently granted patent (Publication Number: US11857543B2) discloses a method for treating anemia secondary to or associated with chronic kidney disease. The method involves orally administering a compound known as {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid to patients with anemia, particularly those with stage 3, 4, or 5 chronic kidney disease or pre-dialysis chronic kidney disease. The compound can be administered once daily and is effective in maintaining hemoglobin levels within a specific range, with adjustments in dosage based on the patient's response.

Furthermore, the patent includes provisions for administering the compound in combination with other medicaments, such as iron supplements, to manage anemia effectively. The method also outlines specific criteria for adjusting the daily dose of the compound based on changes in hemoglobin levels observed in patients over time. The patent covers various scenarios where the dosage may need to be increased or decreased to optimize treatment outcomes. Overall, the method aims to provide a comprehensive approach to managing anemia in patients with chronic kidney disease, offering a structured framework for dosing and monitoring hemoglobin levels to ensure the best possible therapeutic results.

To know more about GlobalData’s detailed insights on Akebia Therapeutics, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies